A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Autor: Andres Poveda, Ana Oaknin, Ignacio Romero, Angel Guerrero-Zotano, Lorena Fariñas-Madrid, Victor Rodriguez-Freixinos, Pedro Mallol, Raquel Lopez-Reig, Jose Antonio Lopez-Guerrero

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin that generates DNA double-strand breaks. W

Externí odkaz: https://doaj.org/article/d1515ed3222c482292aa0ffa3a73aad2

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

Autor: Poveda, Andres¹ apoveda@initiaoncologia.com, Oaknin, Ana², Romero, Ignacio³, Guerrero-Zotano, Angel³, Fariñas-Madrid, Lorena², Rodriguez-Freixinos, Victor⁴, Mallol, Pedro⁵, Lopez-Reig, Raquel^6,7, Lopez-Guerrero, Jose Antonio^6,7,8

Publikováno v: Scientific Reports. 2/24/2021, Vol. 11 Issue 1, p1-11. 11p.

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Autor: Poveda, Andres¹ (AUTHOR) apoveda@initiaoncologia.com, Lopez-Reig, Raquel^2,3 (AUTHOR) rlopez@fivo.org, Oaknin, Ana⁴ (AUTHOR) aoaknin@vhio.net, Redondo, Andres⁵ (AUTHOR) andres.redondos@uam.es, Rubio, Maria Jesus⁶ (AUTHOR) mjesusrubio63@gmail.com, Guerra, Eva⁷ (AUTHOR) eva_m_guerra@hotmail.com, Fariñas-Madrid, Lorena⁴ (AUTHOR) lfarinas@vhio.net, Gallego, Alejandro⁵ (AUTHOR) alejandro.gallego@salud.madrid.org, Rodriguez-Freixinos, Victor^4,8 (AUTHOR) victor.rodriguezfreixinos@sunnybrook.ca, Fernandez-Serra, Antonio^2,3 (AUTHOR) afernandez@fivo.org, Juan, Oscar⁹ (AUTHOR) oscar.juan@pivotalcr.com, Romero, Ignacio¹⁰ (AUTHOR) iromero@fivo.org, Lopez-Guerrero, Jose A.^2,3,11 (AUTHOR) jalopez@fivo.org

Publikováno v: Cancers. Feb2022, Vol. 14 Issue 4, p915. 1p.

A shared origin from a common ancestor: A case report of two histologically different tumors.

Autor: Varea-Martínez M; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain. Electronic address: jalopez@fivo.org., García-Valero E; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain., López-Reig R; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain; Joint IVO-CIPF Cancer Research Unit, Valencia, Spain., Romero I; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain., Machado I; Department of Pathology, Instituto Valenciano de Oncologia, Valencia, Spain., Gómez-Ferrer Á; Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain., Aliaga J; Department of Pathology, Instituto Valenciano de Oncologia, Valencia, Spain., Claramunt-Alonso R; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain., Fernández-Serra A; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain; Joint IVO-CIPF Cancer Research Unit, Valencia, Spain., Marenco-Jiménez JL; Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain., García-Casado Z; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain., López-Guerrero JA; Laboratory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain; Joint IVO-CIPF Cancer Research Unit, Valencia, Spain; Department of Pathology, Catholic University of Valencia, Valencia, Spain. Electronic address: jalopez@fivo.org.

Publikováno v: Pathology, research and practice [Pathol Res Pract] 2023 Aug; Vol. 248, pp. 154648. Date of Electronic Publication: 2023 Jun 30.